277 related articles for article (PubMed ID: 14767344)
1. The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1336-42. PubMed ID: 14767344
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
3. Induction of specific anti-tumour immunity by interferon-gamma gene-transferred murine bladder carcinoma MBT-2.
Hiura M; Hashimura T; Watanabe Y; Kuribayashi K; Yoshida O
Folia Biol (Praha); 1994; 40(1-2):49-61. PubMed ID: 7958064
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
[TBL] [Abstract][Full Text] [Related]
5. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
Lee CF; Chang SY; Hsieh DS; Yu DS
J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of interleukin-12 against murine bladder cancer.
Eto M; Harada M; Tamada K; Tokuda N; Koikawa Y; Nakamura M; Nomoto K; Naito S
J Urol; 2000 May; 163(5):1549-52. PubMed ID: 10751886
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
[TBL] [Abstract][Full Text] [Related]
9. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site.
Halak BK; Maguire HC; Lattime EC
Cancer Res; 1999 Feb; 59(4):911-7. PubMed ID: 10029084
[TBL] [Abstract][Full Text] [Related]
11. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
12. Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma.
Perabo FG; Willert PL; Wirger A; Schmidt DH; Von Ruecker A; Mueller SC
Anticancer Res; 2005; 25(5):3565-73. PubMed ID: 16101181
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect.
Zhu S; Waguespack M; Barker SA; Li S
Clin Cancer Res; 2007 Jul; 13(14):4252-60. PubMed ID: 17634555
[TBL] [Abstract][Full Text] [Related]
14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms.
Metzger DW; McNutt RM; Collins JT; Buchanan JM; Van Cleave VH; Dunnick WA
Eur J Immunol; 1997 Aug; 27(8):1958-65. PubMed ID: 9295032
[TBL] [Abstract][Full Text] [Related]
18. IL-10 protects mouse intestinal epithelial cells from Fas-induced apoptosis via modulating Fas expression and altering caspase-8 and FLIP expression.
Bharhani MS; Borojevic R; Basak S; Ho E; Zhou P; Croitoru K
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G820-9. PubMed ID: 17030898
[TBL] [Abstract][Full Text] [Related]
19. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells.
Lafleur EA; Jia SF; Worth LL; Zhou Z; Owen-Schaub LB; Kleinerman ES
Cancer Res; 2001 May; 61(10):4066-71. PubMed ID: 11358827
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction.
Eguchi J; Hiroishi K; Ishii S; Baba T; Matsumura T; Hiraide A; Okada H; Imawari M
Gene Ther; 2005 May; 12(9):733-41. PubMed ID: 15772692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
